CCG-63802

CAT: 0804-HY-70074-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-70074-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CCG-63802 is a selective, reversible and allosteric RGS4 inhibitor. CCG-63802 specifically binds to RGS4 and blocks the RGS4-Gαo interaction, with an IC50 value of 1.9 μM[1].
CAS Number
[620112-78-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
RGS Protein
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ccg-63802.html
Purity
98.83
Solubility
DMSO : 1.67 mg/mL (ultrasonic; warming)
Smiles
N#C/C(C1=NC2=CC=CC=C2S1)=C\C3=C(N=C4C(C)=CC=CN4C3=O)OC5=CC=CC(C)=C5
Molecular Formula
C26H18N4O2S
Molecular Weight
450.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Levi L Blazer, et al. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol. 2010 Sep;78 (3) :524-33.|[2]Marina Dobrivojević, et al. Interaction between bradykinin and natriuretic peptides via RGS protein activation in HEK-293 cells. Am J Physiol Cell Physiol. 2012 Dec 15;303 (12) :C1260-8.|[3]Xia Meng, et al. PPARγ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model. Inflammation. 2018 Dec;41 (6) :2079-2089.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RGS4

Popular Products